Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 177 clinical trials
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

potential navitoclax effect on QTc prolongation. In Part 4, effect of navitoclax is evaluated on the PK, safety, and tolerability of a single dose of celecoxib in participants with myeloproliferative

stem cell transplantation
ruxolitinib
polycythemia vera
bone marrow procedure
myelofibrosis
  • 49 views
  • 23 Jul, 2022
  • 36 locations
Featured trial
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and …

anemia
  • 0 views
  • 04 Jun, 2022
  • 19 locations
Featured trial
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

myelofibrosis
cell transplantation
  • 0 views
  • 11 Jul, 2022
  • 19 locations
Featured trial
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.   This is an open-label Phase 2 study with 2 cohorts: Cohort A: Itacitinib plus ruxolitinib  Drug: Itacitinib self-administered orally once daily at the   protocol-defined …

myelofibrosis
myeloproliferative disorders
leukemia
  • 172 views
  • 10 May, 2022
  • 9 locations
Featured trial
AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)

AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)

  • 118 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)

AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)

  • 370 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

, and determining its antianemic activity when combined with ruxolitinib in participants with transfusion-dependent or symptomatic anemia due to myeloproliferative disorders.

anemia
  • 81 views
  • 10 May, 2022
  • 2 locations
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 04 Mar, 2022
  • 2 locations
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) (ABNL-MARRO)

collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL

  • 0 views
  • 15 Jul, 2022
  • 1 location
Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').

  • 0 views
  • 12 Jul, 2022
  • 9 locations